- Home
- ACIU vs TSHA Comparison
ACIU vs TSHA Comparison
Compare ACIU & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- TSHA
- Stock Information
- Founded
- ACIU 2003
- TSHA 2019
- Country
- ACIU Switzerland
- TSHA United States
- Employees
- ACIU N/A
- TSHA N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- ACIU Health Care
- TSHA Health Care
- Exchange
- ACIU Nasdaq
- TSHA Nasdaq
- Market Cap
- ACIU 294.9M
- TSHA 313.6M
- IPO Year
- ACIU 2016
- TSHA 2020
- Fundamental
- Price
- ACIU $2.65
- TSHA $1.53
- Analyst Decision
- ACIU Strong Buy
- TSHA Strong Buy
- Analyst Count
- ACIU 2
- TSHA 8
- Target Price
- ACIU $12.00
- TSHA $6.63
- AVG Volume (30 Days)
- ACIU 147.0K
- TSHA 2.3M
- Earning Date
- ACIU 03-13-2025
- TSHA 11-13-2024
- Dividend Yield
- ACIU N/A
- TSHA N/A
- EPS Growth
- ACIU N/A
- TSHA N/A
- EPS
- ACIU N/A
- TSHA N/A
- Revenue
- ACIU $48,505,404.00
- TSHA $9,915,000.00
- Revenue This Year
- ACIU $86.72
- TSHA N/A
- Revenue Next Year
- ACIU $118.28
- TSHA N/A
- P/E Ratio
- ACIU N/A
- TSHA N/A
- Revenue Growth
- ACIU 4097200.00
- TSHA N/A
- 52 Week Low
- ACIU $2.25
- TSHA $1.19
- 52 Week High
- ACIU $4.98
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- ACIU 39.10
- TSHA 34.16
- Support Level
- ACIU $2.56
- TSHA $1.56
- Resistance Level
- ACIU $2.83
- TSHA $1.75
- Average True Range (ATR)
- ACIU 0.16
- TSHA 0.15
- MACD
- ACIU -0.00
- TSHA -0.02
- Stochastic Oscillator
- ACIU 16.85
- TSHA 10.00
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.